-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
Nektar Therapeutics quarterly/annual Nonoperating Income (Expense) history and growth rate from 2010 to 2023.
- Nektar Therapeutics Nonoperating Income (Expense) for the quarter ending September 30, 2024 was -$2.7M, a 161% decline year-over-year.
- Nektar Therapeutics Nonoperating Income (Expense) for the twelve months ending September 30, 2024 was -$15.3M, a 89.5% decline year-over-year.
- Nektar Therapeutics annual Nonoperating Income (Expense) for 2023 was -$12.6M, a 212% decline from 2022.
- Nektar Therapeutics annual Nonoperating Income (Expense) for 2022 was $11.2M.
- Nektar Therapeutics annual Nonoperating Income (Expense) for 2021 was -$77.2M, a 310% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Growth (%)